Phathom Pharmaceuticals (PHAT) Receivables (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Receivables data on file, last reported at $80.7 million in Q1 2026.

• Receivables for Q1 2026 came in at $80.7 million, up 121.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $80.7 million (up 121.99% YoY), and the FY2025 annual result was $78.1 million, up 101.38% from the prior year.
• Receivables rose to $80.7 million in Q1 2026 per PHAT's latest filing, from $78.1 million in the prior quarter.
• Over five years, Receivables peaked at $80.7 million in Q1 2026 and troughed at $1.6 million in Q4 2023.
• A 4-year average of $37.9 million and a median of $37.6 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2024 and 2025: Receivables soared 2270.01% in 2024, then surged 101.38% in 2025.
• A 4-year view of Receivables shows it stood at $1.6 million in 2023, then soared by 2270.01% to $38.8 million in 2024, then surged by 101.38% to $78.1 million in 2025, then grew by 3.32% to $80.7 million in 2026.
• Business Quant data shows PHAT's Receivables at $80.7 million in Q1 2026, $78.1 million in Q4 2025, and $55.8 million in Q3 2025.